Floatz logo

Humax-Cd20

B-Cell Chronic Lymphocytic Leukemia

Emory Universitymonoclonal_antibodyPhase 4 / ApprovedDormant
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
95/ 100

Competitive context

67 Active assets in the B-Cell Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Acalabrutinib
Zulfa Omer
Phase 4BBB
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 4BBB
Rituximab
Zulfa Omer
Phase 4BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 4BBB
Obinutuzumab
Paolo Caimi, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Humax-Cd20 is also rated in:

relapsing-remitting multiple sclerosisActive
BBB
Indicative · Phase 4
74 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative · Phase 3
67 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaActive
BB
Indicative · Phase 3
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →